2. EAU Guidelines, 2017. p. 259. Russian (Клинические рекомендации европейской ассоциации урологов. 2017. 259 с.).

3. Kaprin A.D., Starinsky V.V., Petrova G.V. the State of cancer care in Russia in 2016. M. 2017. 236 p. Russian (Состояние онкологической помощи населению России в 2016 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2017. 236 с.).

4. Burger M. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63:234.

5. Comperat E. Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. Virchows Arch. 2015;466:589.

6. Aaronson D.S. Meta – analysis: does lidocaine gel before flexible cystoscopy provide pain relief? BJU Int. 2009;104:506.

7. Bladder cancer (classics and innovations) / Pod red. M.I. Kogana, M., AMI Medforum, 2017. 262 p. Russian (Рак мочевого пузыря (классика и новации) / под ред. И.И. Когана. М., АМИ «Медфорум», 2017. 262 с.).

8. Yafi F.A. Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. Urol. Oncol. 2015;33:66e25.

9. Tetu B. Diagnosis of urothelial carcinoma from urine. Mod. Pathol. 2009;22(2):S253.

10. Lingley-Papadopoulos C.A., Loew M.H., Manyak M.J., Zara J.M. Computer recognition of cancer in the urinary bladder using optical coherence tomography and texture analysis. J. Biomed Opt. 2008;13(2):024003.

11. Ustinova O.A. Radiologic diagnostics in the planning of surgical treatment of bladder cancer: autorefer. diss. …Cand.Med.Sci. M., 2010. 23 p. Russian (Устинова О.А. Лучевая диагностика в планировании хирургического лечения и мониторинга рака мочевого пузыря: автореф. дисс. ... канд. мед. наук. М., 2010. 23 с.).

12. Nuriev I.P., Sitdykova M.E., Zubkov A.Y. Diagnostics of urinary bladder neoplasms. Prakticheskaya medicina. 2013;1–4 (73):121–126. Russian (Нуриев И.Р., Ситдыкова М.Э., Зубков А.Ю. Диагностика новообразований мочевого пузыря. Практическая медицина. 2013;1–4(73):121–126).

13. Babjuk M., Böhle A., Burger M. et al. EAU guidelines on nonmuscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2016;71:447–461.

14. Kutovoi I.B. Integrated ultrasound in diagnosis and evaluating the prevalence of bladder cancer: autorefer. diss. сand. med.sci. Kazan., 2010. 21 p. Russian (Кутовой И.Б. Комплексная эхография в диагностике и оценке распространенности рака мочевого пузыря: автореф. дисс. канд. мед. наук. Казань, 2010. 21 с.).

15. Mowatt G. et al. Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: Systematic review and meta-analysis. Int. J. Technol. Assess. Health Care. 2011;27:3.

16. Kausch I. et al. Photodynamic diagnosis in non-muscle-invasive of bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur. Urol. 2010;57:595.

17. Richterstetter M. et al. The value of extended transurethral resection of bladder tumour (TURBT) in the treatment of bladder cancer. BJU Int. 2012;110: E76.

18. Kramer M.W. et al. En bloc resection of urothelium carcinoma of the bladder (ERBUC): European multicenter study to compare safety, efficacy and outcome of laser and electrical en bloc transurethral resection of bladder tumor, World J Urol. 2015;33:1937.

19. Hara T. et al. Risk on concomitant carcinoma in situ determining biopsy candidates among primary non-muscle-invasive bladder cancer patients: retrospective analysis of 173 japanese cases. Int. J. Urol. 2009;16:293.

20. Neuzillet Y. et al. Assessment of diagnostic gain with hexaminolevulinate (HAL) in the setting of newly diagnosed non-muscle-invasive bladder cancer with positive results on urine cytology. Urol. Oncol. 2014;32:1135.

21. Chissov V.I. Oncourology: national guideline. М.: GEOTAR-Media, 2012. 688 p. Russian (Чиссов В.И. Онкоурология: национальное руководство. М.: ГЭОТАР-Медиа, 2012. 688 c.).

22. Lopez Beltran A., Montironi R., Cheng L. Microcystic urothelial carcinoma: morphology, immunohistochemistry and clinical behaviour. Histopathology. 2014;64(6):872–879.

23. Mihailenko D.S., Nemtsova M.V. Point somatic mutations in development of bladder cancer: key events of cancerogenesis, diagnostic markers and targets for therapy. Urologiia. 2016;1:100–105. Russian (Михайленко Д.С.,Немцова М.В. Точковые соматические мутации в развитии рака мочевого пузыря: ключевые события канцерогенеза, диагностические маркеры и мишени для терапии. Урология. 2016;1:100–105.

24. Sankhwar M., Sankhwar S.N. Variations in CYP isoforms and bladder cancer: a syperfamily paradigm. Urol. Oncol. 2014;32(1):33–40.

25. Mikhajlenko D.S. Molecular genetic diagnostics in oncourology. Ed. by D.V. Zaletaeva. LAP Lambert academic Publishing, 2013. 72 с. Russian (Михайленко Д.С. Молекулярно-генетическая диагностика в онкоурологии. Под ред. Д.В. Залетаева. LAP Lambert academic Publishing, 2013. 72 с.).

26. Pandith A.A., Zhah Z.A., Siddiqi M.A. Oncogenic role of fibroblast growth factor receptor 3 in tumorigenesis of urinary bladder cancer. Urol. Oncol. 2013;31(4):398–406.

27. Knowles M.A., Hurst C.D. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat. Rev. Cancer. 2015;15(1):25–41.

28. Iyer G., Milowsky M.I. Fibroblast growth factor receptor 3 in urothelial tumorigenesis. Urol. Oncol. 2013;31(3):303–311.

29. Siverberg D.M. Urothelial carcinoma of the upper urinary tract diagnosed via FGFR3 mutation detection in urine: a case report. BMC Urol. 2012;12:20.

30. Kandimalla R., Masius R., Beukers W. A 3-plex methylation assay combined with the FGFR3 mutation assay sensitively detects recurrent bladder cancer in voided urine. Clin. Cancer Res. 2013;19(17):4760–4769.

31. Serizawa R.R., Ralfkiaer U., Steven K. Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events. Int. J. Cancer. 2011;129(1):78–87.

32. Cote R.J., Dunn M.D., Chatterjee S.J., Stein J.P. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer res. 1998;58(6):1090–1094.

33. Saad A.E. Sensitivity and specificity. B.J.U. International. 2002;89(4):369–373.

34. Rosser C.J. Urinary protein biomarker panel for the detection of recurrent bladder cancer. Cancer Epidemiol Biomarkers Prev. 2014;23(7):1340–1345.

35. Shelepova V.M. Clinical value of definition of a soluble fragment of a cytokeratin 19-Cyfra21-1. Laboratoria. 2004;2:3–6. Russian (Шелепова В.М.Клиническое значение определения растворимого фрагмента цитокератина 19-Cyfra 21-1. Лаборатория. 2004; 2: 3–6).

36. Urquidi V., Netherton M., Gomes-Giacoia E. et al. Urinary mRNA biomarker panel for the detection of urothelial carcinoma. Oncotarget. 2016;7:38731–38740.

37. Jiang X., Du L., Wang L. Serum microRNA expression signatures identified from genome-wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer: serum miRNA Signature for BC detection. Int J Cancer. 2015;136(4):854–62. Doi: 10.1002/ijc.29041.

38. McConkey D.J., Choi W., Shen Y. et al. A prognostic gene expression signature in the molecular classification of chemotherapy-naïve urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy: a Phase 2 Trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with Bevacizumab in urothelial cancer. Eur Urol. 2016; 69:855–862. Doi:10.1016/j.eururo.2015.08.034.

39. Christoph F., Weikert S., Wolff I. Urinary cytokeratin 20 mRNA expression has the potential to predict recurrence in superficial transitional cell carcinoma of the bladder. Cancer Lett. 2007;245:121–126. Doi:10.1016/j.canlet.2005.12.038.

40. Pu X.-Y., Wang Z.-P., Chen Y-R. The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine. J Cancer Res Clin Oncol. 2008;134:659–665. Doi:10.1007/s00432-007-0331-9.

41. Karayan-Tapon L., Menet E., Guilhot J., Levillain P., Larsen C.J., Kraimps J.L.Topoisomerase II α and telomerase expression in papillary thyroid carcinomas. J. Canc. Surg.Onc. 2004;30(1):73–79. dx.doi.org/10.1016/j.ejso.2003.10.002.

42. Ito Y. Telomerase activity in thyroid neoplasms evaluated by the expression of human telomerase reverse transcriptase (hTERT). Anticancer res. 2005;25(1B):509–514.

43. Yang J., Liu X., Bhalla K., Kim C.N., Ibrado A.M., Cai J., Peng T.I. Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked. Science. 1997;275(5303):1129–1132. dx.doi.org/10.1126/science.275.5303.1129.

44. Hiyama T., Yokozaki H., Shimamoto F., Haruma K., Yasui W., Kajiyama G.,Tahara E. Frequent p53 gene mutations in serrated adenomas of the colorectum. J. of Patholog. 1998;186(2):131–139. dx.doi.org/10.1002/(SICI)1096-9896(1998100)186:2%3C131::AID-PATH158%3E3.3.CO;2-T.

45. Hanh W.C. Creation of human tumor cells with defined genetic elements. Nature. 1999;400:464–468.

46. Botchkina G.I., Kim R.H., Botchkina I. L. et al. Noninvasive detection of prostate cancer by quantitative analysis of telomerase activity. Clin. Canc. Res. 2005;11(9):3243–3249. dx.doi.org/10.1158/1078-0432.CCR-04-1919.

47. Sommerfeld H.J. Telomerase activity: a prevalent marker of malignant human prostate tissue. Canc. Res.1996;56:218–222.

48. Glybochko P.V., Zezerov E.G., Glukhov A.I., Alyaev Yu G., Severin S.E., Polyakovsky K.A., Varshavsky V.A., Severin E.S., Vinarov A.Z. Telomerase as a Tumor Marker in Diagnosis of Prostatic Intraepithelial Neoplasia and Prostate Cancer. The Prostate. 2014;74:1043–1051.

49. Kamradt J., Drosse C., Kalkbrenner S., Rohde V. Telomerase activity and telomerase subunit gene expression levels are not related in prostate cancer: a real-time quantification and in situ hybridization study. Lab. Invest. 2003;83:623–633. dx.doi.org/10.1097/01.LAB.0000069035.85309.30.

50. Alyaev Yu.G., Bezrukov E.A., Shestiperov P.A. Molecular pathology of a prostate cancer: diagnostic and predictive importance of the main markers. Onkourologiya. 2006;2:45–51. Russian (Аляев Ю.Г., Безруков Е.А., Шестиперов П.А. Молекулярная патология рака предстательной железы: диагностическая и прогностическая значимость основных маркеров. Онкоурология. 2006;2:45–51).

51. Mekhail T.M., Kawanishi-Tabata R., Tubbs R., Novick A. Renal cell carcinoma (RCC) and telomerase activity: relationship to stage. Urol. Oncol. 2003;21:424–430. dx.doi.org/10.1016/S1078-1439(03)00003-6.

52. Chen C.H., Chen RJ. Prevalence of Telomerase Activity in Human Cancer. J. Formos. Med. Assoc. 2011;110(5):275–289. dx.doi.org/10.1016/S0929-6646(11)60043-0.

53. Iwabuchi I. Significance of A simple assay of urine telomerase activity for the detection of bladder cancer. Act. Urol. Jap. 2010;56(10):551–557.

54. Yoshida K., Sugino T., Tahara H. Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cells in urine. Cancer 1997;79:362–369.

55. Halling K.C., King W., Sokolova I.A., Karnes R.J., Meyer R.G., Powell E.L., Sebo T.J., Cheville J.C., Clayton A.C., Krajnik K.L., Ebert T.A., Nelson R.E., Burkhardt H.M., Ramakumar S., Stewart C.S., Pankratz V.S., Lieber M.M., Blute M.L., Zincke H., Seelig S.A., Jenkins R.B., O’Kane D.J. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol. 2002;167:2001–2006.

56. Ramakumar S., Bhuijan J., Besse J.A., Roberts S.G., Wollan P.C., Blute M.L. Comparison of screening methods in the detection of bladder cancer. J Urol. 1999;161:388–394.

57. Landman J., Chang Y., Kavaler E., Droller M.J., Liu B.C.S. Sensitivity and specifi city of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology. 1998;52:398–420.

58. Kavaler E., Landman J., Chang Y., Droller M.J., Liu B.C. Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity. Cancer. 1998;82:708.

59. Cassel A., Rahat M.A., Lahat N., Lindenfeld N., Mecz Y., Stein A. Telomerase activity and cytokeratin 20 as markers for the detection and follow-up of transitional cell carcinoma: An unfulfi lled promise. J Urol. 2001;166:841.

60. Eissa S., Swellam M., Amin A., Balbaa ME., Ahmed G., Tarek Y., El-Zayat M. The clinical relevance of urine-based markers for diagnosis of bladder cancer. Med. Onc. 2011;28;2:513–518. dx.doi.org/10.1007/s12032-010-9422-6.

61. Brems-Eskildsen A.S., Zieger K., Toldbod H., Holcomb C., Higuchi R. Prediction and diagnosis of bladder cancer recurrence based on urinary content of hTERT, SENP1, PPP1CA, and MCM5 transcripts. BMC Cancer. 2010;10:ar646.

62. Lamarca A., Barriuso J. Urine Telomerase for Diagnosis and Surveillance of Bladder Cancer. Adv Urol. 2012:693631. dx.doi.org/10.1155/2012/693631.

63. Glas A.S., Roos D., Deutehom M., Zwinderman A.H., Bossujt P.M., Kurth K.H. Tumor markers in the diagnosis of primary bladder cancers. A systematic review. J Urol. 2003;169:1975–1982.

64. Wiener H.G., Mian C., Haitel A., Pycha A., Schatzl G., Marberger M. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? J Urol. 1998;159:1876–1880.

65. Eissa S., Swellam M., Sadek M., Mourad S., Ahmadij O., Khalifa A. Comparative evaluation of the nuclear matrix protein, fi bronectin, urinary bladder cancer antigen and voided urinary cytology in the detection of bladder tumors. J Urol. 2002;168:465–469.

66. Poulakis V., Witzsch U., Vries D., Altmannsberger H.-M., Manjak M.J., Becht E.A comparison of urinary nuclear matrix protein-22 and bladder tumor antigen test with voided urinary cytology in detecting and following bladder cancer: The prognostic value of false-positive results. BJU Int. 2001;88:692–701.

67. Silvestrini R. The current role of telomerase in the diagnosis of bladder cancer. Ind. J. Urol. 2009;25(1):40–46.

68. Glukhov A.I., Grigorieva Y.E., Gordeev S.A., Vinarov A.Z., Potoldykova N.V. Noninvasive Diagnostics of Bladder Cancer Based on Analysis of Telomerase Activity and Expression hTERT and hTR Coding Its Subunits Biochemistry. 2014(Supplemental Series B, (Russian Federation):8(1):59–68.

69. Glukhov A.I., Zimnik O.V., Gordeev S.A., Severin S.E. Inhibition of Telomerase Activiti of Melanoma Cells in Vitro by Antisense Oligonucleotides. Biochem. Biophys. Res. Communs. 1998;248:368–371.

70. Friedman K.M., Fox B.A. The promising future of proteomics in cancer diagnosis and treatment. Eur. J Gastroenterol. Hepatol. 2005;17(7):701–703. dx.doi.org/10.1097/00042737-200507000-00002.

71. Glukhov A.I., Zimnik O.V., Severin S.E. Inhibition of tumor cell telomerase activity by biological active compounds. XXIX ISOBM MEETING. International Society for oncodevelopmental Biology and Medicine. Barcelona, 2001. Abstract Book. P. 200.